A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

A

Allegro Ophthalmics

Status and phase

Completed
Phase 2

Conditions

Dry Age-related Macular Degeneration

Treatments

Drug: Risuteganib
Other: Sham

Study type

Interventional

Funder types

Industry

Identifiers

NCT03626636
Dry AMD

Details and patient eligibility

About

To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration

Full description

Approximately 40 eligible subjects who have been diagnosed with intermediate Non-Exudative AMD, that require treatment will be enrolled and randomized (1.7:1) to one of 2 treatment groups: Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate® Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection At the 16-week visit, the study will be unmasked to the sponsor and injecting investigator (observing investigators will remain masked). Subjects in the treatment group will receive a 2nd dose of Luminate®. Subjects in the control group will be offered the opportunity to crossover to treatment with a single dose of Luminate®.

Enrollment

42 patients

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female patients, 50 to 85 years of age at screening visit
  • Subject has signed the Informed Consent form
  • Subjects with Non-Exudative AMD having ETDRS BCVA between 33 and 72 letters read (equivalent to 20/40 - 20/200 on Snellen Chart) with the level of vision caused by the non-exudative AMD and no other factor/s
  • Subjects with symptomatic decrease in visual acuity in the last 12 months
  • Subjects with combination of areas of RPE disturbances (hyper or hypopigmentation) and/or > 1 large druse(n) (>125 microns) and/or multiple intermediate drusen (62-124 microns) in the macula as confirmed by the central reading center

Subjects with evidence of reasonably well-preserved areas of RPE by clinical examination and well-defined RPE and outer segment ellipsoid line by OCT examination in the central 1 mm of the macula as confirmed by the central reading center. More specifically, reasonable reasonably well- preserved central 1 mm of the macula means:

  • The RPE and outer retinal layers throughout the central 1 mm are intact
  • No signs of NVAMD such as intraretinal or sub retinal fluid, or sub retinal hyper-reflective material
  • No serous pigment epithelium detachments >100 microns in height

Exclusion criteria

  • Females who are pregnant, nursing, planning a pregnancy during the study or who are of childbearing potential not using a reliable method of contraception and/or not willing to maintain a reliable method of contraception during their participation in the study. Women of childbearing potential with a positive urine pregnancy test administered at baseline are not eligible to receive study drug.
  • Participation in an investigational drug or device study within 90 days of screening
  • Subjects with active exudative AMD in the fellow eye
  • Subjects who had anti-VEGF IVT in either eye in the past 90 days
  • Subjects with pigment epithelium detachments
  • Subjects with active exudative AMD
  • Subjects with any prior retina surgery
  • Subjects with pathology that could prevent observation and follow-up of macular structures and measurement of BCVA (i.e. advanced primary open angle glaucoma, any stage of normal tension glaucoma and corneal opacification)
  • Subjects that are likely to require cataract surgery in the opinion of the investigator within the study protocol period

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

42 participants in 2 patient groups, including a placebo group

Active Group
Active Comparator group
Description:
Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
Treatment:
Drug: Risuteganib
Placebo Group
Placebo Comparator group
Description:
Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
Treatment:
Other: Sham

Trial documents
1

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems